Glycogen storage disease type 1a (von Gierke disease, GSD1a), one of the most common types of glycogen storage diseases, is caused by the deficiency of microsomal glucose-6-phosphatase (G6Pase ...

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

New precision genome editing technologies are transforming the therapeutic landscape for patients with certain cancers and ...

Learn more about whether Moderna, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Beam Therapeutics Inc.’s BEAM share price has dipped by 11.15%, which has investors questioning if this is right time to buy.

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the ...

Cats, whether big or small, long or short-haired, talkative or silent, clingy or distant, have won over the hearts of 220 ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I am upgrading BEAM.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The MetaVision3D tool transforms 2D tissue sections into 3D brain metabolome models, offering critical insights into ...

The company is evaluating BEAM-101 in an early-stage study targeting sickle cell disease and BEAM-301 in another early-stage study targeting glycogen storage disease 1a, a rare disease where a ...

Discover a recent first-in-human gene therapy trial that has shown promising results in improving glucose homeostasis.